I have read your uploaded gpt.txt and used it as the starting list for this review. It contains the institutions and clinicians from your earlier chat, including Columbia/NYSPI/Lieber, Mount Sinai, NYU, Zucker Hillside, OnTrackNY, and the seven principal physician names you wanted checked.[ppl-ai-file-upload.s3.amazonaws]
The strongest documented matches to your goals are:
The essential distinction is that AMP SCZ is a biomarker-development research program—not a validated, comprehensive clinical diagnostic-and-treatment package. I did not verify any NYC provider offering your entire proposed imaging–C4–microglia–medication–network-restoration sequence as established clinical care. The official AMP SCZ description focuses on developing tools for people at clinical high risk for psychosis.[ampscz][fnih]
Your goal—combining symptom control with cognitive and functional recovery—is a useful organizing principle. However, the profile should separate documented clinical services from research capabilities and mechanistic hypotheses.
| Requested component | What the documentation supports | How it should appear in your resource profile |
|---|---|---|
| High-resolution T1/T2 structural MRI, diffusion MRI, resting-state fMRI | These genuinely are components of the AMP SCZ imaging protocol. The published protocol describes approximately 46–48 minutes of acquisition, with imaging at baseline and approximately two months. [escholarship] | “AMP SCZ research imaging capability,” not automatically “clinically validated schizophrenia diagnostic imaging.” |
| Functional striatal abnormalities or default-mode-network shifts | AMP SCZ uses multimodal biomarkers to investigate prediction and clinical outcomes. The sources do not establish FSA/DMN findings as routine individual diagnostic readouts that determine treatment. [pmc.ncbi.nlm.nih][nature] | Ask whether these are research analyses, whether individual results are returned, and whether any result has validated treatment implications. |
| C4 structural-variant mapping | The landmark C4 work links structurally diverse C4 alleles, predicted C4A expression, and schizophrenia risk. That is not equivalent to demonstrating active excessive pruning in a particular patient. [pmc.ncbi.nlm.nih] | “Research genetic expertise”; do not label a center a clinical C4-guided treatment service without specific documentation. |
| Inflammatory/microglial profiling | Mount Sinai documents blood/fluid biomarker research; NYU documents autoantibody and immune-mechanism research. These are different approaches and should not be collapsed into a single validated “microglial over-pruning test.” [reports.mountsinai][med.nyu] | Identify the actual assay, clinical indication, interpretation, and whether it is research-only. |
| Computerized cognition and behavioral assessment | AMP SCZ includes cognitive and clinical assessments; Lieber and OnTrackNY have documented cognition-focused services. [pmc.ncbi.nlm.nih][pmc.ncbi.nlm.nih][lieberclinic] | Separate research phenotyping from clinical neuropsychological assessment and treatment planning. |
| Cobenfy | FDA-approved for schizophrenia in adults; approval is for schizophrenia, not a distinct “fear circuit” indication. [fda][fda] | A medication option for specialist assessment, not a mandatory component of a comprehensive program. |
| “Monocycline” | The likely intended medication is minocycline; the evidence discussion below concerns minocycline. Its proposed anti-pruning role is not an established clinical benefit. [pmc.ncbi.nlm.nih][mdpi] | Experimental/off-label discussion, not proven synapse-preservation treatment. |
| CRT, rehabilitation, social cognition, CBTp | Lieber explicitly documents these clinical modalities, including supported work/school services. [columbiadoctors][lieberclinic] | Established service categories to seek and verify at intake. |
| rTMS to regenerate networks | A Northwell schizophrenia study examines cognition, cerebellar function, and fMRI changes. That does not establish regeneration or synapse restoration as a demonstrated clinical outcome. [allclinicaltrials] | Schizophrenia-specific research or carefully defined off-label treatment—not generic TMS availability. |
The 207-participant BeneMin randomized trial found no benefit of adjunctive minocycline for negative symptoms and no improvement in symptomatic or functional status in its recent-onset schizophrenia population. Its primary biomarker outcomes were also unaffected.[pmc.ncbi.nlm.nih][research.birmingham.ac]
A 2026 review likewise describes the evidence as heterogeneous, with modest and inconsistent signals rather than reproducible efficacy sufficient for routine clinical use; direct evidence for suppression of excessive pruning remains limited. Consequently, I would not use willingness to prescribe minocycline as a quality criterion for selecting an expert.[mdpi]
Cobenfy is different: it has an established adult-schizophrenia indication, supported by randomized trials. Nevertheless, those studies do not establish that it should be paired with minocycline or that the pair prevents synaptic loss.[fda][pmc.ncbi.nlm.nih]
Qualification: retain as a core center, particularly for the research-intensive evaluation you described.
Mount Sinai’s own report documents:
This is substantially stronger evidence of AMP SCZ capability than simply having a major MRI center or a prominent schizophrenia department.
Mount Sinai documents specialized services spanning early and chronic psychosis, with medication, social interventions, and psychotherapy. Its Psychosis Risk Program specifically lists diagnostic evaluation, psychiatric consultation/medication management, individual/family psychoeducation, and CBT for psychosis-risk.[mountsinai][mountsinai]
The cited AMP SCZ report describes research participation and anticipated trial activity; it does not establish that enrollment is open today, that an adult with established schizophrenia qualifies, or that a clinical patient can purchase the full protocol. It also does not document clinical C4 structural typing or a validated microglial-pruning assessment service.[reports.mountsinai]
Qualification: retain as a core center, but separate the university/research institution from the actual clinic delivering care.
Lieber’s published service list closely matches the recovery portion of your plan:
Its computerized cognitive-remediation groups use the NEAR model, with individualized exercises and clinician-supported learning rather than undifferentiated “brain games.”[lieberclinic]
These two are more directly aligned with your CRT-and-capacity-building goals than a list limited to famous medication researchers.
Lieber states that it is primarily self-pay, accepts specified Aetna/student/university plans, and does not accept Medicaid or Medicare. Some services may not be reimbursable even with out-of-network benefits. This is a meaningful correction to the more general insurance language in your uploaded summary.[ppl-ai-file-upload.s3.amazonaws][lieberclinic]
Lieber’s documented clinical strengths do not establish that the clinic itself provides AMP SCZ acquisition, C4 structural-variant mapping, microglial assays, or schizophrenia-targeted rTMS. I would list those as separate research/referral questions, not as Lieber services.[columbiadoctors][lieberclinic]
Qualification: retain as a core center, with particularly clear individual consultation options.
NYU’s Schizophrenia Research Group documents work involving:
The group works across NYU hospitals, Bellevue, Manhattan Psychiatric Center, and the Nathan Kline Institute. These are related research settings, not interchangeable patient-access points.[med.nyu]
Goff’s current clinical profile explicitly states that he specializes in schizophrenia and primarily offers consultation and second opinions. That makes him one of the most clearly documented matches for an expert review of diagnosis, medication history, and research opportunities.[nyulangone]
Nemani is board-certified in psychiatry and neurology. Her clinical profile includes schizophrenia and neuropsychiatric evaluation; her research focuses on immune mechanisms in psychiatric illness, particularly psychosis.[nyulangone]
She is a particularly relevant person to ask whether an immune-focused differential evaluation is appropriate. That should not be interpreted as evidence that all schizophrenia is autoimmune or that a positive research antibody finding necessarily indicates immunotherapy. NYU describes this work as an effort to identify new treatment targets.[med.nyu][nyulangone]
The research page does not demonstrate a routinely available clinical AMP SCZ bundle, clinical C4-guided prescribing, or a validated treatment sequence combining Cobenfy, minocycline, and neuromodulation.[med.nyu]
Qualification: retain as a core center.
First, an important geographic correction: Zucker Hillside’s Glen Oaks campus is in Queens, NYC. Your uploaded document incorrectly describes it as outside NYC on Long Island. Its OnTrackNY listing gives 75-59 263rd Street, Glen Oaks, NY 11004.[ppl-ai-file-upload.s3.amazonaws][ontrackny]
The official AMP SCZ consortium roster identifies NORTHWELL as a ProNET recruitment site. The ProNET protocol also identifies John Kane at Northwell as one of the principal investigators and Northwell as an administrative hub. This supports inclusion on the AMP SCZ list—not merely the general schizophrenia list.[ampscz][cdn.clinicaltrials]
John Kane is therefore another important addition to your expert roster, particularly in a research-leadership category. The protocol alone does not establish his availability for a private consultation.[cdn.clinicaltrials]
A registry-derived listing identifies:
The listing’s status was verified in September 2025, so I cannot certify current recruitment from that record. Also, another third-party trial directory mismatched trial titles and identifiers; I would not rely on that directory’s “recruiting” labels.[allclinicaltrials][clinicaltrialsfinder][cdn.clinicaltrials]
| Entity | Verdict | Appropriate role |
|---|---|---|
| OnTrackNY | Retain; do not call it “Tier 2” simply because it is not a biomarker center. | Coordinated specialty care for early psychosis: medication, therapy, work/school goals, family and peer support. Typical eligibility is ages 16–30 with non-affective psychosis for less than two years. [ontrackny][cases] |
| Bellevue | Retain as a clinical/research access setting; avoid treating it as identical to NYU’s private consultation practice. | NYU explicitly identifies Bellevue as a schizophrenia-research setting. The precise clinic and services need to be specified before assigning individual capabilities. [med.nyu] |
| Manhattan Psychiatric Center | Retain and correct the claim that it is not a schizophrenia research center. | NYU identifies Jean-Pierre Lindenmayer as director of the Manhattan Schizophrenia Research Program at MPC/Nathan Kline. MPC also provides adult inpatient and community/outpatient care. [med.nyu][omh.ny] |
| Weill Cornell/NewYork-Presbyterian | Retain, particularly for severe/treatment-refractory illness and rehabilitation; distinguish Manhattan from Westchester. | Its Psychotic Disorders Division documents schizophrenia-focused inpatient and partial-hospital services. The Westchester Second Chance program combines psychopharmacology and intensive behavioral rehabilitation; the partial-hospital program includes CBT and cognitive remediation. [psychiatry.weill.cornell] |
The original heading “Private Practice Physicians Who Are Genuine Published Schizophrenia Experts” is too broad. Research distinction, a faculty appointment, an active clinical practice, and acceptance of new consultation patients are separate facts.[ppl-ai-file-upload.s3.amazonaws]
| Name | Qualifies? | Correct placement and qualification |
|---|---|---|
| Donald Goff | Yes | NYC schizophrenia clinician-scientist; current NYU profile explicitly offers consultation and second opinions. [nyulangone] |
| Christoph Correll | Yes | Northwell schizophrenia/psychopharmacology expert, including refractory illness. His profile also documents a Berlin appointment; verify where and whether he personally sees new patients. [feinstein.northwell] |
| Jeffrey Lieberman | Yes, with access qualification | Current ColumbiaDoctors listing identifies him as a Columbia psychiatry professor at NYSPI. Keep on the expert roster, but the listing alone does not confirm new-patient availability or the proposed advanced testing package. [doctors.columbia] |
| Anissa Abi-Dargham | Yes, but relocate | Major schizophrenia/molecular-imaging expert now based at Stony Brook; Columbia professor emerita. Place under “regional/Long Island research experts,” not current NYC-based Columbia care. [doctors.stonybrookmedicine][renaissance.stonybrookmedicine] |
| René Kahn | Yes | Strong schizophrenia neurobiology and AMP SCZ leadership credentials. Personal outpatient consultation availability is not established by the research documentation. [reports.mountsinai] |
| Sophia Frangou | Yes, research-focused | Mount Sinai profile supports schizophrenia, cognition, brain connectivity, genetic imaging, and multimodal research. Do not assume an accessible private schizophrenia consultation service. [profiles.mountsinai] |
| Katlyn Nemani | Yes | NYC clinical neuropsychiatrist with schizophrenia expertise and a particularly relevant immune-mechanism research focus. [nyulangone] |
| Tiffany Herlands | Yes | Directly relevant clinical rehabilitation/cognitive specialist; she is a psychologist, not a prescribing psychiatrist. [columbiapsychiatry][lieberclinic] |
| Cheryl Corcoran | Yes | Especially relevant to psychosis risk and AMP SCZ multimodal assessment. [reports.mountsinai][profiles.mountsinai] |
| Dolores Malaspina | Yes | Psychosis clinician-scientist and Critical Connections program leader. [health.mountsinai] |
Add Alice Medalia for cognitive remediation, John Kane for AMP SCZ/ProNET and schizophrenia research leadership, and Jean-Pierre Lindenmayer for the Manhattan Schizophrenia Research Program. These additions make the roster better aligned with your particular goals rather than simply expanding the number of prestigious names.[cdn.clinicaltrials][columbiapsychiatry][med.nyu]
| Modality | Best-supported resource from this review | Limitation |
|---|---|---|
| Expert medication/diagnostic second opinion | Goff/NYU; Northwell psychopharmacology expertise; Mount Sinai schizophrenia services. [nyulangone][feinstein.northwell][mountsinai] | Cobenfy-specific prescribing experience was not verified for individual clinicians. |
| Computerized cognitive remediation | Lieber/NEAR; Northwell BOOST may include it; cognition-focused care is documented across OnTrackNY implementation work. [lieberclinic][zucker.northwell][pmc.ncbi.nlm.nih] | Ask whether a particular site currently offers a full course, not only screening or referral. |
| CRT combined with real-world rehabilitation | Lieber; Weill Cornell/NYP psychosis partial-hospital and rehabilitation programs. [columbiadoctors][psychiatry.weill.cornell] | Campus, intensity, eligibility, and payment differ. |
| Social-cognition training | Lieber explicitly lists Social Cognition and Interaction Training. [columbiadoctors][lieberclinic] | Availability and group schedule need confirmation. |
| CBT for psychosis and collaborative belief testing | Lieber lists CBTp; Mount Sinai documents CBT for psychosis-risk. [lieberclinic][mountsinai] | Ask about the actual CBTp therapist and protocol; risk-state CBT and established-psychosis CBT are not identical services. |
| Schizophrenia-targeted rTMS | Northwell’s cerebellar TMS study is a concrete research lead. [allclinicaltrials] | Current enrollment unconfirmed; not established “network regeneration.” |
| Exercise integrated with schizophrenia recovery | Not verified as a defined schizophrenia-specific exercise protocol at the shortlisted centers in this review. | Recreational therapy or general wellness services should not be relabeled a structured exercise intervention. |
| C4-guided anti-pruning treatment | No verified clinical provider identified. | C4 association research does not itself establish a treatment-selection test. [pmc.ncbi.nlm.nih] |
| Minocycline for synapse preservation | No verified evidence-based clinical program identified. | Negative randomized evidence and inconsistent broader findings prevent treating this as standard disease modification. [pmc.ncbi.nlm.nih][mdpi] |
Fountain House is a strong fit for the capacity-building part of your plan: relationships, supported education, transitional/supported employment, and connections to other services. It operates programs in Manhattan, the Bronx, and Harlem.[fountainhouse][fountainhouse]
NYC’s clubhouse system serves adults with serious mental illness and provides education and employment assistance. It belongs in a recovery-support section, not the advanced diagnostic-testing section.[nyc]
NAMI-NYC provides free peer-led support, family education, caregiver support, and navigation assistance. It is relevant to sustaining treatment engagement and helping families navigate services, not to MRI, genetics, or prescribing.[naminycmetro][naminycmetro]
I would replace the original single numerical ranking with three parallel lists:
For each entry, the profile should record:
We are seeking a schizophrenia-spectrum specialist evaluation with coordinated medication treatment, CBT for psychosis, cognitive assessment/remediation, social-cognition work, and functional rehabilitation.
- Do you evaluate established schizophrenia, clinical-high-risk states, or both?
- Are you currently enrolling in AMP SCZ/ProNET or related multimodal biomarker studies?
- Does your available protocol include T1/T2 structural MRI, diffusion MRI, resting-state fMRI, EEG, and standardized cognition?
- Which results are returned as clinically interpretable individual findings?
- Do you offer C4 structural-variant testing or immune assays clinically, or only in research—and what would the findings change?
- Which named clinicians provide CBTp, cognitive remediation, social-cognition training, and supported work/school rehabilitation?
- Do you offer schizophrenia-specific rTMS research or treatment, rather than TMS for a different indication?
- Who would serve as the coordinating psychiatrist, and what are the access and payment requirements?
This approach preserves your ambitious recovery goals while avoiding the most important error in the original framework: treating access to sophisticated research measurements as proof that a clinic can diagnose active synaptic over-pruning or deliver a validated synapse-restoration treatment.[ampscz][pmc.ncbi.nlm.nih][pmc.ncbi.nlm.nih]